Recro Pharma, Inc. Insider Trading for March 2014
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Recro Pharma, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in Recro Pharma, Inc. for March 2014.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 13 2014 | REPH | Recro Pharma, Inc. | CHURCHILL WINSTON J | Director | Option Exercise | C | 5.00 | 1,875,000 | 9,375,000 | 0 | |
| Mar 13 2014 | REPH | Recro Pharma, Inc. | CHURCHILL WINSTON J | Director | Option Exercise | A | 8.00 | 20,000 | 160,000 | 20,000 | |
| Mar 13 2014 | REPH | Recro Pharma, Inc. | CHURCHILL WINSTON J | Director | Buy | C | 0.00 | 2,045,738 | 0 | 3,167,286 | 1.1 M to 3.2 M (+182.40 %) |
| Mar 13 2014 | REPH | Recro Pharma, Inc. | CHURCHILL WINSTON J | Director | Buy | C | 0.00 | 1,121,548 | 0 | 1,121,548 | 0 to 1.1 M |
| Mar 13 2014 | REPH | Recro Pharma, Inc. | Ashton William | Director | Option Exercise | A | 8.00 | 20,000 | 160,000 | 20,000 | |
| Mar 13 2014 | REPH | Recro Pharma, Inc. | Berelowitz Michael | Director | Option Exercise | A | 8.00 | 20,000 | 160,000 | 20,000 | |
| Mar 13 2014 | REPH | Recro Pharma, Inc. | ALTOMARI ALFRED | Director | Option Exercise | A | 8.00 | 20,000 | 160,000 | 20,000 | |
| Mar 13 2014 | REPH | Recro Pharma, Inc. | SCP Vitalife Partners (Israel) ... | 10% Owner | Option Exercise | C | 5.00 | 469,469 | 2,347,345 | 0 | |
| Mar 13 2014 | REPH | Recro Pharma, Inc. | SCP Vitalife Partners (Israel) ... | 10% Owner | Buy | C | 0.00 | 512,414 | 0 | 793,240 | 280.8 K to 793.2 K (+182.47 %) |
| Mar 13 2014 | REPH | Recro Pharma, Inc. | SCP Vitalife Partners (Israel) ... | 10% Owner | Buy | C | 0.00 | 280,826 | 0 | 280,826 | 0 to 280.8 K |
| Mar 13 2014 | REPH | Recro Pharma, Inc. | LUDOMIRSKI ABRAHAM | Director | Option Exercise | C | 5.00 | 1,875,000 | 9,375,000 | 0 | |
| Mar 13 2014 | REPH | Recro Pharma, Inc. | LUDOMIRSKI ABRAHAM | Director | Option Exercise | A | 8.00 | 20,000 | 160,000 | 20,000 | |
| Mar 13 2014 | REPH | Recro Pharma, Inc. | LUDOMIRSKI ABRAHAM | Director | Buy | C | 0.00 | 2,045,738 | 0 | 3,167,286 | 1.1 M to 3.2 M (+182.40 %) |
| Mar 13 2014 | REPH | Recro Pharma, Inc. | LUDOMIRSKI ABRAHAM | Director | Buy | C | 0.00 | 1,121,548 | 0 | 1,121,548 | 0 to 1.1 M |
| Mar 13 2014 | REPH | Recro Pharma, Inc. | Garner Charles | CFO and Chief Busin ... | Option Exercise | A | 8.00 | 81,026 | 648,208 | 81,026 | |
| Mar 13 2014 | REPH | Recro Pharma, Inc. | Nichols Donna | CAO/Controller | Option Exercise | A | 8.00 | 8,000 | 64,000 | 8,000 | |
| Mar 13 2014 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | President and CEO | Option Exercise | A | 8.00 | 60,000 | 480,000 | 60,000 | |
| Mar 13 2014 | REPH | Recro Pharma, Inc. | Myers Diane | Senior VP-Reg./Qual ... | Option Exercise | A | 8.00 | 12,000 | 96,000 | 12,000 | |
| Mar 13 2014 | REPH | Recro Pharma, Inc. | Weisman Wayne | Director | Option Exercise | C | 5.00 | 1,875,000 | 9,375,000 | 0 | |
| Mar 13 2014 | REPH | Recro Pharma, Inc. | Weisman Wayne | Director | Option Exercise | A | 8.00 | 20,000 | 160,000 | 20,000 | |
| Mar 13 2014 | REPH | Recro Pharma, Inc. | Weisman Wayne | Director | Buy | C | 0.00 | 2,045,738 | 0 | 3,167,286 | 1.1 M to 3.2 M (+182.40 %) |
| Mar 13 2014 | REPH | Recro Pharma, Inc. | Weisman Wayne | Director | Buy | C | 0.00 | 1,121,548 | 0 | 1,121,548 | 0 to 1.1 M |
| Mar 13 2014 | REPH | Recro Pharma, Inc. | SCP Vitalife Partners II LP | 10% Owner | Option Exercise | C | 5.00 | 1,405,531 | 7,027,655 | 0 | |
| Mar 13 2014 | REPH | Recro Pharma, Inc. | SCP Vitalife Partners II LP | 10% Owner | Buy | C | 0.00 | 1,533,324 | 0 | 2,374,046 | 840.7 K to 2.4 M (+182.38 %) |
| Mar 13 2014 | REPH | Recro Pharma, Inc. | SCP Vitalife Partners II LP | 10% Owner | Buy | C | 0.00 | 840,722 | 0 | 840,722 | 0 to 840.7 K |
| Mar 13 2014 | REPH | Recro Pharma, Inc. | Mack Randall | Senior VP, Developm ... | Option Exercise | A | 8.00 | 20,000 | 160,000 | 20,000 |